Nonprofit challenges Gilead’s patents on sofosbuvir

Media Article 27 Oct 2017

“As an organization, we’ve been working on the issue of patents and medicines for over 10 years and we have identified that unmerited patents can be a driver of high drug prices, particularly where they’re unnecessarily blocking drug competition,” Tahir Amin, co-founder and co-executive director of I-MAK told “Through our research we have identified a number of examples where the over-patenting situation on drugs is getting in the way of more access and more competition in the marketplace, which naturally results in morefold prices.”

Partner with us now to build
a more just and equitable
medicine system for all.